Inactive Instrument

All News Clementia Pharmaceuticals Inc

Equities

CA1855751071

All News

Unlock all the news on all businesses: Never miss an investment opportunity again!

Clementia Pharmaceuticals Inc. Announces Receipt of Final Court Approval for Plan of Arrangement With Ipsen S.A.	19-04-11	GL
Clementia Pharmaceuticals Inc. Shareholders Approve Plan of Arrangement With Ipsen S.A.	19-04-09	GL
WeissLaw LLP Investigates Clementia Pharmaceuticals, Inc.	19-03-01	PR
Trade tariff reprieve triggers relief in European shares	19-02-25	RE
GLOBAL MARKETS LIVE: Roche, AT&T, Spotify, General Electric…	19-02-25
Clementia Pharmaceuticals : Ipsen to buy Clementia Pharmaceuticals in deal worth up to $1.3 billion	19-02-25	RE
Clementia Announces Date of Fourth Quarter and Full Year 2018 Results and Presentation at 8th Annual SVB Leerink Global Healthcare Conference	19-02-20	GL
Clementia Announces the Departure of Chief Commercial Officer	18-11-30	GL
Clementia to Present at the Evercore ISI HealthCONx Conference	18-11-21	GL
Clementia Reports Third Quarter 2018 Operating Results and Pipeline Updates	18-11-07	GL
Clementia Announces Pricing of Public Offering of Common Shares	18-10-29	GL
Clementia Announces Proposed Public Offering of Common Shares	18-10-29	GL
Clementia Announces Plan to Submit a New Drug Application for Palovarotene for the Treatment of FOP Based on Positive Phase 2 Results	18-10-23	GL
Clementia Initiates Phase 1 Clinical Trial of Palovarotene Eye Drop Formulation in Healthy Volunteers	18-10-02	GL
Clementia Announces Updated Phase 2 Part B Data on Palovarotene for FOP	18-09-26	GL
Clementia to Present at ASBMR 2018 and Upcoming Investor Conferences	18-09-05	GL
Clementia Announces Completion of Enrollment in Phase 3 MOVE Trial for FOP	18-08-16	GL
Clementia Reports Second Quarter 2018 Operating Results and Pipeline Updates	18-08-09	GL
Clementia to Present at the Jefferies 2018 Global Healthcare Conference	18-05-31	GL
Clementia Reports Positive Phase 2 Part B Data Showing Treatment with Palovarotene Significantly Reduces New Bone Growth in Patients with FOP	18-05-23	GL

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

All News Clementia Pharmaceuticals Inc

Equities

CA1855751071

All News

Filters